Patent ID: 11963980
Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C

Claim 0:
1. A method of treating cancer in a subject comprising administering an effective amount of T cells to the subject, wherein at least 10 percent of the T cells are CD26high T cells, wherein said T cells have been isolated from a peripheral blood mononuclear cell (PBMC) population, and wherein said T cells have been activated and expanded in culture in the presence of anti-CD3 beads, anti-CD28 beads, and/or anti-ICOS beads at a beads to T cell ratio of 1:5 to 1:25 prior to administering to the subject, wherein no antigen-specific stimulation has been performed on said T cells which have increased secretion of IL-17A, IFN-γ, and IL-2 after activation and expansion.